Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2022 Aug 12

PMID 35960489

Authors

Hannah A Blair

Affiliations

Soon will be listed here.

Abstract

Onasemnogene abeparvovec (Zolgensma) is a gene therapy approved for the treatment of spinal muscular atrophy (SMA). Administered as a one-time intravenous infusion, onasemnogene abeparvovec uses the adeno-associated virus vector to deliver a functional copy of the human survival motor neuron (SMN) gene to motor neuron cells. SMN1 encodes survival motor neuron protein, which is responsible for the maintenance and function of motor neurons. In clinical trials, onasemnogene abeparvovec improved event-free survival, motor function and motor milestone outcomes in patients with SMA, with these improvements maintained over the longer term (up to a median of ≈ 5 years). Onasemnogene abeparvovec was also associated with rapid age-appropriate achievement of motor milestones and improvements in motor function in children with pre-symptomatic SMA, indicating the benefit of early treatment. Onasemnogene abeparvovec was generally well tolerated. Hepatotoxicity is a known risk that can generally be mitigated with prophylactic prednisolone. In conclusion, onasemnogene abeparvovec represents an important treatment option for patients with SMA, particularly when initiated early in the course of the disease.

Citing Articles

Motor Function and Safety of Nusinersen and Risdiplam in Asian Patients with Types 2-4 Spinal Muscular Atrophy (SMA): A Systematic Review and Meta-Analysis.

Zhao X, Liao Y, Zhao J, Zhu L, Liu J, Zhang M Adv Ther. 2025; .

PMID: 39960588 DOI: 10.1007/s12325-024-03101-7.

Advancements in PROTAC-based therapies for neurodegenerative diseases.

Kong D, Meng L, Lin P, Wu G Future Med Chem. 2025; 17(5):591-605.

PMID: 39931801 PMC: 11901405. DOI: 10.1080/17568919.2025.2463310.

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database.

Zhang W, Yin Y, Yang D, Liu M, Ye C, Yan R Front Pharmacol. 2025; 15():1475884.

PMID: 39840097 PMC: 11747325. DOI: 10.3389/fphar.2024.1475884.

Adeno-Associated Viral Vectors in the Treatment of Epilepsy.

Mullagulova A, Timechko E, Solovyeva V, Yakimov A, Ibrahim A, Dmitrenko D Int J Mol Sci. 2024; 25(22).

PMID: 39596149 PMC: 11593886. DOI: 10.3390/ijms252212081.

Experiences and the psychosocial situation of parental caregivers of children with spinal muscular atrophy against the background of new treatment options: a qualitative interview study.

Brandt M, Driemeyer J, Johannsen J, Denecke J, Inhestern L, Bergelt C BMC Psychol. 2024; 12(1):566.

PMID: 39420400 PMC: 11488358. DOI: 10.1186/s40359-024-02070-4.

References

Govoni A, Gagliardi D, Comi G, Corti S . Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy. Mol Neurobiol. 2018; 55(8):6307-6318. DOI: 10.1007/s12035-017-0831-9. View

Keinath M, Prior D, Prior T . Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. Appl Clin Genet. 2021; 14:11-25. PMC: 7846873. DOI: 10.2147/TACG.S239603. View

Schorling D, Pechmann A, Kirschner J . Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis. 2019; 7(1):1-13. PMC: 7029319. DOI: 10.3233/JND-190424. View

Kirschner J, Butoianu N, Goemans N, Haberlova J, Kostera-Pruszczyk A, Mercuri E . European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020; 28:38-43. PMC: 7347351. DOI: 10.1016/j.ejpn.2020.07.001. View

Calucho M, Bernal S, Alias L, March F, Vencesla A, Rodriguez-Alvarez F . Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018; 28(3):208-215. DOI: 10.1016/j.nmd.2018.01.003. View

Costa-Roger M, Blasco-Perez L, Cusco I, Tizzano E . The Importance of Digging into the Genetics of Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int J Mol Sci. 2021; 22(16). PMC: 8396600. DOI: 10.3390/ijms22169029. View

Kichula E, Proud C, Farrar M, Kwon J, Saito K, Desguerre I . Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021; 64(4):413-427. PMC: 8518380. DOI: 10.1002/mus.27363. View

Serra-Juhe C, Tizzano E . Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur J Hum Genet. 2019; 27(12):1774-1782. PMC: 6871529. DOI: 10.1038/s41431-019-0415-4. View

Bevan A, Duque S, Foust K, Morales P, Braun L, Schmelzer L . Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011; 19(11):1971-80. PMC: 3222525. DOI: 10.1038/mt.2011.157. View

10.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

11.

Thomsen G, Burghes A, Hsieh C, Do J, Chu B, Perry S . Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021; 27(10):1701-1711. DOI: 10.1038/s41591-021-01483-7. View

12.

Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T . Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 377(18):1713-1722. DOI: 10.1056/NEJMoa1706198. View

13.

Day J, Finkel R, Chiriboga C, Connolly A, Crawford T, Darras B . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(4):284-293. DOI: 10.1016/S1474-4422(21)00001-6. View

14.

Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(10):832-841. DOI: 10.1016/S1474-4422(21)00251-9. View

15.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1381-1389. PMC: 9205281. DOI: 10.1038/s41591-022-01866-4. View

16.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1390-1397. PMC: 9205287. DOI: 10.1038/s41591-022-01867-3. View

17.

Lowes L, Alfano L, Arnold W, Shell R, Prior T, McColly M . Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatr Neurol. 2019; 98:39-45. DOI: 10.1016/j.pediatrneurol.2019.05.005. View

18.

Al-Zaidy S, Pickard A, Kotha K, Alfano L, Lowes L, Paul G . Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2018; 54(2):179-185. PMC: 6590370. DOI: 10.1002/ppul.24203. View

19.

Mendell J, Al-Zaidy S, Lehman K, McColly M, Lowes L, Alfano L . Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021; 78(7):834-841. PMC: 8129901. DOI: 10.1001/jamaneurol.2021.1272. View

20.

Matesanz S, Battista V, Flickinger J, Jones J, Kichula E . Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy. Pediatr Neurol. 2021; 118:1-5. DOI: 10.1016/j.pediatrneurol.2021.01.012. View